ROSUVASTATIN is among additions to the list of drugs which will become subject to a weighed average disclosed price calculation due to meeting the F2/multi branded criteria (30 month clock) for the 2017 Apr Cycle.
The Dept of Health will publish the outcomes for the cycle in mid to late Dec - pbs.gov.au.
The above article was sent to subscribers in Pharmacy Daily's issue from 17 Oct 16
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 17 Oct 16
